Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Director | June 17, 2026 | June 18, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director · President and CEO | November 27, 2018 | November 30, 2018 |
| Kailera Therapeutics, Inc.KLRA · Entity 4435 | Director | April 16, 2026 | April 20, 2026 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB · Entity 5650 | Director | June 03, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.42 · Expires 2036-06-16 | Direct | 75,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 75,000 · Balance 75,000 F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).
GILEAD SCIENCES, INC.
Report date November 27, 2018 · Filed November 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,574,306 |
Reported balance
After 2018-11-27 transaction · row 1
1 source rowRow 1 · 2018-11-27 · Exercise / conversion · Acquired 280,000 · Balance 1,574,306 |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.60 · Expires 2019-01-21 | Direct | 0 |
Reported balance
After 2018-11-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-11-27 · Exercise / conversion · Disposed 280,000 · Balance 0 F1: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
Kailera Therapeutics, Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-04-16 | Direct | 38,300 |
Reported balance
After 2026-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 38,300 · Balance 38,300 F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2036-06-03 | Direct | 223,492 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 223,492 · Balance 223,492 F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 21, 2013 Filed Nov 25, 2013 18:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 395,634 | $71.57 | $28,316,395.77 |
DisclosureSEC source: 0001179110-13-016995 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 564,774 F3 · price: Sale prices reported for the transactions reported here range from $71.37 to $71.85. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 21, 2013 Filed Nov 25, 2013 18:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 395,634 | $7.63 | $3,019,676.51 |
DisclosureSEC source: 0001179110-13-016995 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 960,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2013 Filed Nov 18, 2013 20:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 395,635 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001179110-13-016634 · edgar.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,634 Underlying: Common Stock · 395,635 shares Expires 2014-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| November 14, 2013 Filed Nov 18, 2013 20:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 395,635 | $68.86 | $27,242,832.65 |
DisclosureSEC source: 0001179110-13-016634 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 564,774 F3 · price: Sale prices reported for the transactions reported here range from $68.75 to $69.10. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 14, 2013 Filed Nov 18, 2013 20:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 395,635 | $7.63 | $3,019,684.14 |
DisclosureSEC source: 0001179110-13-016634 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 960,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2013 Filed Nov 12, 2013 17:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 395,635 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001179110-13-016383 · edgar.xml · derivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 791,269 Underlying: Common Stock · 395,635 shares Expires 2014-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| November 07, 2013 Filed Nov 12, 2013 17:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 177,842 | $68.18 | $12,125,996.71 |
DisclosureSEC source: 0001179110-13-016383 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 564,774 F4 · price: Sale prices reported for the transactions reported here range from $67.51 to $68.40. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 07, 2013 Filed Nov 12, 2013 17:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 217,793 | $66.97 | $14,584,878.49 |
DisclosureSEC source: 0001179110-13-016383 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742,616 F3 · price: Sale prices reported for the transactions reported here range from $66.50 to $67.50. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 07, 2013 Filed Nov 12, 2013 17:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 395,635 | $7.63 | $3,019,684.14 |
DisclosureSEC source: 0001179110-13-016383 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 960,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 22:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 25,568 | $45.40 | $1,160,787.20 |
DisclosureSEC source: 0001179110-13-004729 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 564,774 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 22:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 49,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-004729 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,342 F1 · shares: Vesting of performance share awards on March 6, 2013 F2 · balance_after: Amount of securities beneficially owned following the reported transaction includes 968 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on February 15, 2013. Read SEC document |
| February 01, 2013 Filed Feb 5, 2013 22:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 149,620 | $0.00 Strike: $40.56 | $0.00 |
DisclosureSEC source: 0001179110-13-001941 · edgar.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,620 Underlying: Common Stock · 149,620 shares Expires 2023-02-01 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 30, 2013 Filed Jan 24, 2014 22:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 34,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-001365 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 624,528 F1 · shares: Represents shares of the Issuer's common stock subject to a specific tranche of the performance share award made to the Reporting Person on January 26, 2012. Such tranche of shares was subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was deemed satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be actually issued to the Reporting Person until such individual satisfies the applicable service-vesting requirement by continuing in the Issuer's employ through December 31, 2014. Read SEC document |
| November 02, 2012 Filed Nov 6, 2012 20:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $17.50 | $0.00 |
DisclosureSEC source: 0001179110-12-015729 · edgar.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2013-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Dr. Milligan on May 25, 2012 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| November 02, 2012 Filed Nov 6, 2012 20:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 70,000 | $67.01 | $4,690,672.00 |
DisclosureSEC source: 0001179110-12-015729 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,187 F3 · price: Sale prices reported for the transactions reported here range from $66.84 to $67.253. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 02, 2012 Filed Nov 6, 2012 20:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 70,000 | $17.50 | $1,224,825.00 |
DisclosureSEC source: 0001179110-12-015729 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2012 Filed Oct 31, 2012 16:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 11,180 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001179110-12-015491 · edgar.xml · derivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,180 shares Expires 2013-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| October 29, 2012 Filed Oct 31, 2012 16:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 11,180 | $8.94 | $99,977.15 |
DisclosureSEC source: 0001179110-12-015491 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2012 Filed Oct 5, 2012 17:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $17.50 | $0.00 |
DisclosureSEC source: 0001179110-12-014935 · edgar.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2013-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Dr. Milligan on May 25, 2012 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| October 03, 2012 Filed Oct 5, 2012 17:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 70,000 | $69.85 | $4,889,241.00 |
DisclosureSEC source: 0001179110-12-014935 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,007 F3 · price: Sale prices reported for the transactions reported here range from $69.67 to $69.99. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 03, 2012 Filed Oct 5, 2012 17:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 70,000 | $17.50 | $1,224,825.00 |
DisclosureSEC source: 0001179110-12-014935 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 04, 2012 Filed Sep 7, 2012 00:33 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $17.50 | $0.00 |
DisclosureSEC source: 0001179110-12-013754 · edgar.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2013-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Dr. Milligan on May 25, 2012 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| September 04, 2012 Filed Sep 7, 2012 00:33 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 140,000 | $57.41 | $8,037,694.00 |
DisclosureSEC source: 0001179110-12-013754 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,007 F3 · price: Sale prices reported for the transactions reported here range from $57.07 to $57.87. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 04, 2012 Filed Sep 7, 2012 00:33 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 140,000 | $17.50 | $2,449,650.00 |
DisclosureSEC source: 0001179110-12-013754 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2012 Filed Jul 3, 2012 23:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 733 | $29.02 | $21,270.93 |
DisclosureSEC source: 0001179110-12-011183 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,007 F1 · kind: Amount of securities beneficially owned following the reported transaction includes 733 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on June 29, 2012. Read SEC document |
| March 12, 2012 Filed Mar 15, 2012 00:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 16,456 | $46.16 | $759,608.96 |
DisclosureSEC source: 0001179110-12-005062 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,480 Read SEC document |
| March 12, 2012 Filed Mar 15, 2012 00:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 35,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-005062 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,936 F1 · shares: Issuance of common stock upon vesting of performance share awards on March 12, 2012 Read SEC document |
| January 26, 2012 Filed Jan 30, 2012 23:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 151,250 | $0.00 Strike: $48.59 | $0.00 |
DisclosureSEC source: 0001179110-12-001319 · edgar.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,250 Underlying: Common Stock · 151,250 shares Expires 2022-01-26 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 06, 2012 Filed Jan 10, 2012 19:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,120 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001179110-12-000631 · edgar.xml · derivative · entry 7 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,120 shares Expires 2012-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 30, 2003 the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 30, 2007. Read SEC document |
| January 06, 2012 Filed Jan 10, 2012 19:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 4,160 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001179110-12-000631 · edgar.xml · derivative · entry 6 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,160 shares Expires 2012-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 30, 2003 the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 30, 2007. Read SEC document |
| January 06, 2012 Filed Jan 10, 2012 19:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001179110-12-000631 · edgar.xml · derivative · entry 5 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,160 Underlying: Common Stock · 1,500 shares Expires 2012-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 30, 2003 the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 30, 2007. Read SEC document |
| January 06, 2012 Filed Jan 10, 2012 19:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,120 | $8.22 | $9,205.06 |
DisclosureSEC source: 0001179110-12-000631 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2012 Filed Jan 10, 2012 19:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 4,160 | $8.22 | $34,190.21 |
DisclosureSEC source: 0001179110-12-000631 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2012 Filed Jan 10, 2012 19:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,500 | $8.22 | $12,328.20 |
DisclosureSEC source: 0001179110-12-000631 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2011 Filed Dec 22, 2011 19:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001179110-11-017017 · edgar.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,660 Underlying: Common Stock · 6,500 shares Expires 2012-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 30, 2003 the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 30, 2007. Read SEC document |
| December 21, 2011 Filed Dec 22, 2011 19:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 6,500 | $8.22 | $53,422.20 |
DisclosureSEC source: 0001179110-11-017017 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2011 Filed Mar 17, 2011 23:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 10,492 | $39.79 | $417,476.68 |
DisclosureSEC source: 0001179110-11-005184 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,284 Read SEC document |
| March 15, 2011 Filed Mar 17, 2011 23:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-005184 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,776 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on March 15, 2011. Read SEC document |
| March 15, 2011 Filed Apr 5, 2011 21:19 UTC Amendment | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 12,602 | $39.79 | $501,433.58 |
DisclosureSEC source: 0001179110-11-006030 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,674 F2 · shares: The transactions listed in Table 1 are restated in its entirety to show the correct number of shares issued and beneficially owned. Read SEC document |
| March 15, 2011 Filed Apr 5, 2011 21:19 UTC Amendment | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-006030 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,276 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on March 15, 2011. F2 · shares: The transactions listed in Table 1 are restated in its entirety to show the correct number of shares issued and beneficially owned. Read SEC document |
| January 20, 2011 Filed Jan 25, 2011 00:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 192,000 | $0.00 Strike: $38.17 | $0.00 |
DisclosureSEC source: 0001179110-11-001271 · edgar.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,000 Underlying: Common Stock · 192,000 shares Expires 2021-01-20 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on January 20, 2012 the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested on January 20, 2015. The options expire on January 20, 2021. Read SEC document |
| December 20, 2010 Filed Dec 22, 2010 23:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock · Derivative | 7,352 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001179110-10-018071 · edgar.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,352 shares Expires 2011-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options have a 5 year vesting schedule. 20% of the options vested on April 18, 2002, the first anniversay of the grant. The balance vested every three months thereafter until fully vested on April 18, 2006. The options expire on April 17, 2011. Read SEC document |
| December 20, 2010 Filed Dec 22, 2010 23:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 7,352 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-018071 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 111,755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2010 Filed Mar 11, 2010 01:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-004954 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,102 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on March 8, 2010. Read SEC document |
| January 28, 2010 Filed Feb 2, 2010 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 140,000 | $0.00 Strike: $47.51 | $0.00 |
DisclosureSEC source: 0001179110-10-001747 · edgar.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2020-01-28 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 28, 2011 the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 28, 2015. Read SEC document |
| December 24, 2009 Filed Dec 29, 2009 01:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001179110-09-017495 · edgar.xml · derivative · entry 6 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,352 Underlying: Common Stock · 7,000 shares Expires 2011-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on April 18, 2002, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on April 18, 2006. Read SEC document |
| December 24, 2009 Filed Dec 29, 2009 01:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,732 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001179110-09-017495 · edgar.xml · derivative · entry 5 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,732 shares Expires 2010-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on November 8, 2001, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on November 8, 2005. Read SEC document |
| December 24, 2009 Filed Dec 29, 2009 01:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 8,016 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001179110-09-017495 · edgar.xml · derivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,016 shares Expires 2011-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 18, 2002, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 18, 2006. Read SEC document |
| December 24, 2009 Filed Dec 29, 2009 01:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 7,000 | $4.91 | $34,335.00 |
DisclosureSEC source: 0001179110-09-017495 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 24, 2009 Filed Dec 29, 2009 01:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,732 | $5.88 | $16,061.43 |
DisclosureSEC source: 0001179110-09-017495 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.